Our Cold Plasma Medical Device leads the way

Bacteria protected within biofilm are up to 1000x more resistant to antibiotics. This can complicate treatment options for wounds and surgical site infections but as it is an international form of therapy, it remains used throughout patient treatments despite it offering little to no help in healing problematic/stalled wounds and infections.

The cost burden associated to ongoing antibiotic therapy is significant as is the antimicrobial resistance rates that are ever growing. The World Health Organisation recognizes this and more hospitals are reaching out to alternative therapies to help curb the spending costs and antimicrobial resistance rates.

As the Adtec SteriPlas cold plasma has been shown to kill all forms of bacteria, regardless of their resistance profile or if they are Gram -ve or +ve or even if they are protected within biofilm, it has become widely adopted as an alternative to antibiotic therapy specifically in cases where patients are at a severe stage of infection such as those associated to diabetic foot ulcers and left ventricular assist device infections.

It has been praised as a life-saving medical device helping to heal infections that have been stalled for a very long time where conventional therapies have failed to act, reduce amputation and mortality rates.

This year we look forward to releasing a series of Health Economic publications documenting the cost effectiveness of our medical device against the use conventional therapies. We look forward to releasing this information to you in due time.

Until then, please reach out to us to learn more about why the interest in our medical device is growing daily. The data collection of our safety and efficacy shows why using an Adtec SteriPlas could completely change the way you treat patients.